Specify Company / Ticker to Get the Summary
Dividend History VIR
Dividend Analytics VIR
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Vir Biotechnology Inc
VIRVir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Address: 1800 Owens Street, San Francisco, CA, United States, 94158
Analytics
WallStreet Target Price
17.88 USDP/E Ratio
–Dividend Yield
–Financials VIR
Results | 2019 | Dynamics |